Glenmark launches generic cancer treatment drug in US

Glenmark Pharmaceuticals on Tuesday launched Eribulin Mesylate Injection, a generic cancer treatment, in the US through its subsidiary Glenmark Pharmaceuticals Inc., USA. The product, equivalent to Eisai’s Halaven Injection, will begin distribution this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GA9Vtaz
via IFTTT